Reactivación del virus de la hepatitis B tras el cese de la profilaxis con entecavir en un paciente con leucemia linfoblástica tipo Burkitt tratado con rituximab / Hepatitis B virus reactivation after cessation of prophylaxis with entecavir in a patient with Burkitt type acute lymphoblastic leukaemia treated with rituximab

No disponible

Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.

OBJECTIVES: Acid-reducing agents (ARAs) and proton-pump inhibitors (PPIs) that increase gastric pH can alter the bioavailability of antiviral drugs, particularly relevant in patients with advanced liver disease caused by chronic hepatitis C virus (HCV) infection seeking therapy. Using integrated data from six phase 3 studies, we report the safety and efficacy of the 3-direct-acting antiviral (DAA) regimen containing ombitasvir (OBV, an NS5A inhibitor), ritonavir-boosted paritaprevir (PTV/r, an NS3/4A protease inhibitor), and dasabuvir (DSV, an NS5B polymerase inhibitor) with or without ribavirin (RBV) for HCV genotype 1 patients taking concomitant ARAs and PPIs. METHODS: Treatment-naïve or peginterferon/RBV treatment-experienced patients with or without compensated cirrhosis received OBV/PTV/r and DSV with or without weight-based RBV. Rates of sustained virologic response (SVR), defined as HCV RNA below the lower limit of quantification, 12 weeks post-treatment (SVR12) and safety were evaluated in patients who were receiving concomitant ARAs. RESULTS: Among 2,053 patients enrolled and dosed with study drug, 410 (20%) were receiving concomitant ARAs; of these, 308 (15%) were taking concomitant PPIs. Rates of SVR12 were 95.9% (95% confidence interval (CI) 93.5-97.4%) among patients receiving an ARA, and 96.3% (95% CI 95.3-97.2%) in patients not receiving a concomitant ARA. Similarly, among patients receiving a PPI or not, SVR12 was achieved in 95.1% (95% CI 92.1-97.0%) and 96.4% (95% CI 95.5-97.2%), respectively. Response rates were high regardless of treatment regimen (with or without RBV), and among patients receiving a standard or high dose of PPIs. Regarding safety, adverse events and serious adverse events were more frequently reported in patients taking concomitant ARAs, though baseline population differences may have played a role. CONCLUSIONS: In phase 3 trials of OBV/PTV/r plus DSV and RBV in HCV genotype 1-infected patients, SVR12 rates were high regardless of ARA/PPI use or PPI dose. These data support the co-administration of this regimen with ARAs including PPIs.

Factores pronósticos asociados a la mortalidad de los pacientes con hepatitis alcohólica grave / Prognostic factors associated with mortality in patients with severe alcoholic hepatitis

La hepatitis alcohólica grave se asocia a una mortalidad precoz elevada. El objetivo de nuestro estudio fue identificar los factores pronósticos asociados a la mortalidad intrahospitalaria, la mortalidad a medio y a largo plazo de la hepatitis alcohólica grave, así como evaluar los diferentes índices pronósticos en una cohorte de pacientes de nuestro hospital. Realizamos un análisis de 66 episodios consecutivos que ingresaron durante el periodo 2000-2008. Se recogieron y analizaron los datos clínicos y analíticos al ingreso, a la semana, al mes, a los 6 meses y al año, así como datos sobre el tratamiento recibido y las complicaciones asociadas durante el ingreso. Se calcularon y evaluaron los diferentes índices pronósticos de la literatura. La mortalidad asociada a un episodio de hepatitis alcohólica grave se produjo sobre todo durante el primer mes, con una tasa media de mortalidad del 16,9 %. Las complicaciones infecciosas se relacionaron con una menor supervivencia intrahospitalaria. Los valores de MELD, urea y bilirrubina a los 7 días de ingreso fueron los únicos factores independientes de supervivencia intrahospitalaria (OR = 1,14; 1,012 y 1,1, respectivamente) y a los 6 meses (OR = 1,15; 1,014 y 1,016, respectivamente). A los 12 meses, solo los valores de MELD y urea a los 7 días fueron factores independientes de supervivencia. En nuestra cohorte el MELD fue el mejor índice pronóstico para predecir la mortalidad asociada a un episodio de hepatitis alcohólica grave (AU)

Severe alcoholic hepatitis is associated with high early mortality. This study aimed at identifying prognostic factors associated with in-hospital, medium- and long-term mortality of severe alcoholic hepatitis and to evaluate the different prognostic scoring systems on a cohort of patients in our hospital. To this end, we conducted a retrospective analysis of 66 episodes admitted between 2000 and 2008. Clinical and laboratory data on admission, at 7 days, 1 month, 6 months, and after one year were collected and analyzed, as were the details on the treatment and complications that occurred during hospitalization; the different prognostic indices used in the literature were calculated. Death event associated with an episode of severe alcoholic hepatitis occurs primarily during the first month, with an average mortality rate of 16.9. Infectious complications were associated with lower in-hospital survival. MELD score, urea and bilirubin values one week after admission were independently associated with both in-hospital survival (OR = 1.14, 1.012 and 1.1, respectively), and survival at 6 months (OR = 1, 15; 1.014 and 1.016, respectively). Only MELD score and urea values at 7 days were independent predictors of survival twelve months after the acute hepatitis episode. MELD score, urea, and bilirubin 7 days after admission were the only independent in-hospital survival and also long-term survival factors 6 months and one year after the episode. In our cohort, the MELD score was the best prognostic index to predict mortality associated with an episode of severe alcoholic hepatitis (AU)

[Prognostic factors associated with mortality in patients with severe alcoholic hepatitis]. / Factores pronósticos asociados a la mortalidad de los pacientes con hepatitis alcohólica grave.

Severe alcoholic hepatitis is associated with high early mortality. This study aimed at identifying prognostic factors associated with in-hospital, medium- and long-term mortality of severe alcoholic hepatitis and to evaluate the different prognostic scoring systems on a cohort of patients in our hospital. To this end, we conducted a retrospective analysis of 66 episodes admitted between 2000 and 2008. Clinical and laboratory data on admission, at 7 days, 1 month, 6 months, and after one year were collected and analyzed, as were the details on the treatment and complications that occurred during hospitalization; the different prognostic indices used in the literature were calculated. Death event associated with an episode of severe alcoholic hepatitis occurs primarily during the first month, with an average mortality rate of 16.9. Infectious complications were associated with lower in-hospital survival. MELD score, urea and bilirubin values one week after admission were independently associated with both in-hospital survival (OR = 1.14, 1.012 and 1.1, respectively), and survival at 6 months (OR = 1, 15; 1.014 and 1.016, respectively). Only MELD score and urea values at 7 days were independent predictors of survival twelve months after the acute hepatitis episode. MELD score, urea, and bilirubin 7 days after admission were the only independent in-hospital survival and also long-term survival factors 6 months and one year after the episode. In our cohort, the MELD score was the best prognostic index to predict mortality associated with an episode of severe alcoholic hepatitis.

[How many reach their goal? Outcome of abstracts presented at the XXIV AAEEH (Spanish Liver Study Association) Congress and their progress over time]. / 'Cuántos alcanzan la meta? Destino de los resúmenes presentados en el XXIV Congreso de la Asociación Española para el Estudio del Hígado y su evolución en el tiempo.

INTRODUCTION: The aim of the abstracts presented at scientific meetings is their publication in a peer-review journal. In this study, we analysed the publication rates of the abstracts submitted to the 24th AEEH meeting (1999) and also to see if this was stable over time. MATERIAL AND METHODS: We assessed the publication rates of the abstracts presented at the 24th AEEH meeting in journals included in MEDLINE. As a comparison tool, we did the same with the abstracts submitted to the 34th Annual Meeting of the European Association for the Study of the Liver (EASL). The same procedure was carried out on the three subsequent editions of AEEH meetings to evaluate the continuity in the long term. RESULTS: Of the abstracts submitted at the 24th AEEH meeting, 52.8% (93/176) were published: 71.4% of those had been accepted for oral presentation, 54% as a poster and 41% were non-accepted abstracts. From the 34th EASL Annual Meeting, 27.1% (248/913) of the submitted abstracts were published (p < 0.001 compared to AEEH), 52.5% of those were accepted for oral communication, 33.1% accepted as a poster communication and 18.1% from non-accepted abstracts. Moreover, this high publication rate of the abstracts of AEEH meeting at 1999, was maintained during the following three years (47.55 and 54%, respectively). CONCLUSIONS: a) The publication rate of abstracts presented at 24th AEEH meeting was excellent and superior in comparison to the EASL rate of the same year; b) almost three quarters of abstracts accepted for oral presentation and more than half of those accepted as a poster were finally published, and c) high publication rates seem to be maintained over time.

¿Cuántos alcanzan la meta? Destino de los resúmenes presentados en el XXIV Congreso de la Asociación Española para el Estudio del Hígado y su evolución en el tiempo / How many reach their goal? Outcome of abstracts presented at the XXIV AAEEH (Spanish Liver Study Association) Congress and their progress over time

Introducción: El objetivo de los resúmenes presentados a los congresos científicos es su publicación en una revista basada en la revisión previa por expertos. En el presente estudio se analizó la tasa de publicación de los resúmenes presentados al XXIV Congreso de la Asociación Española para el Estudio del Hígado (AEEH) (1999) y si dicha tasa se mantiene a lo largo del tiempo. Material y métodos: Se evaluó la tasa de publicación en revistas incluidas en MEDLINE de los resúmenes presentados al XXIV Congreso de la AEEH. Como comparación se realizó el mismo proceso con los resúmenes presentados al 34th Annual Meeting de la European Association for the Study of the Liver (EASL). Para valorar la continuidad en el tiempo se procedió de igual forma para las siguientes 3 ediciones del Congreso de la AEEH. Resultados: En el XXIV Congreso de la AEEH se publicaron el 52,8% (93/176) de los resúmenes presentados: un 71,4% de los aceptados para sesión oral, un 54% de los aceptados para póster y un 41% de los resúmenes no aceptados. En el 34th Annual Meeting de la EASL se publicaron el 27,1% (248/913) de los resúmenes presentados (p < 0,001 respecto a la AEEH), el 52,5% de los aceptados para la comunicación oral, el 33,1% de los aceptados para la comunicación en póster y el 18,1% de los no aceptados. Además, el alto índice de publicación de los resúmenes del congreso de la AEEH en 1999 se mantuvo durante los siguientes 3 años (el 47,55 y el 54%, respectivamente). Conclusiones: a) La tasa de publicación de los resúmenes presentados al XXIV Congreso de la AEEH fue excelente y superior al de la EASL del mismo año; b) cerca de las tres cuartas partes de los resúmenes aceptados para la sesión oral y algo más de la mitad de los aceptados para la sesión en póster fueron publicados, lo que refleja el alto grado de acierto del Comité de Selección, y c) esta elevada tasa de publicación parece mantenerse en el tiempo

Introduction: The aim of the abstracts presented at scientific meetings is their publication in a peer-review journal. In this study, we analysed the publication rates of the abstracts submitted to the 24th AEEH meeting (1999) and also to see if this was stable over time. Material and methods: We assessed the publication rates of the abstracts presented at the 24th AEEH meeting in journals included in MEDLINE. As a comparison tool, we did the same with the abstracts submitted to the 34th Annual Meeting of the European Association for the Study of the Liver (EASL). The same procedure was carried out on the three subsequent editions of AEEH meetings to evaluate the continuity in the long term. Results: Of the abstracts submitted at the 24th AEEH meeting, 52.8% (93/176) were published: 71.4% of those had been accepted for oral presentation, 54% as a poster and 41% were non-accepted abstracts. From the 34th EASL Annual Meeting, 27.1% (248/913) of the submitted abstracts were published (p < 0.001 compared to AEEH), 52.5% of those were accepted for oral communication, 33.1% accepted as a poster communication and 18.1% from non-accepted abstracts. Moreover, this high publication rate of the abstracts of AEEH meeting at 1999, was maintained during the following three years (47.55 and 54%, respectively). Conclusions: a) The publication rate of abstracts presented at 24th AEEH meeting was excellent and superior in comparison to the EASL rate of the same year; b) almost three quarters of abstracts accepted for oral presentation and more than half of those accepted as a poster were finally published, and c) high publication rates seem to be maintained over time